Juno Lighting Inc | TalkMarkets

Latest Posts

Week In Review: Innovent Out-Licenses Ex-China Rights For PD-1 To Lilly In $1 Billion Deal

Article By: ChinaBio® Today

Saturday, August 22, 2020 1:53 PM EDT

Suzhou Innovent Bio expanded its 2015 alliance with Eli Lilly for Tyvyt®, Innovent's anti-PD-1 immunotherapy. In return for a $1+ billion package, Lilly will have an exclusive license to develop Tyvyt in ex-China markets.

In this article: HBM, LLY, JUNO, JD, EYPT

Read

Week In Review: BeiGene Signs $540 Million Deal For China Rights To Three HBV Candidates

Article By: ChinaBio® Today

Saturday, July 25, 2020 1:21 PM EDT

Beijing's BeiGene in-licensed Greater China rights to three inhibitors for chronic hepatitis B virus from Assembly Bio in a $540 million agreement. BeiGene, which will make a $40 million upfront payment, is responsible for $500 million in milestones.

In this article: CASI, JUNO, HCM, BGNE, ASMB

Read

Week In Review: Suzhou Innovent Announces $2 Billion Immunotherapy Collaboration With Roche

Article By: ChinaBio® Today

Saturday, June 13, 2020 1:32 PM EDT

Suzhou Innovent Bio formed a far-reaching R&D collaboration with Roche that has a potential value of over $2 billion. Roche will have an option to license each product for ex-China development and commercialization.

In this article: RHHBY Also: LLY, SNY, BRN, JUNO

Read

Clovis: Evaluating The Prospects Of A Possible Acquisition

Article By: Dr. Hung Tran

Thursday, January 16, 2020 9:27 AM EDT

Riding robust data, Rubraca is most likely to gain approval for resistant prostate cancer having the BRCA mutation. Here I present a scientific analysis to merger and acquisition to give you more insight into Clovis.